|
1
|
Martelli M, Ferreri AJ, Agostinelli C, Di
Rocco A, Pfreundschuh M and Pileri SA: Diffuse large B-cell
lymphoma. Crit Rev Oncol Hematol. 87:146–171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alizadeh AA, Eisen MB, Davis RE, Ma C,
Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al:
Distinct types of diffuse large B-cell lymphoma identified by gene
expression profiling. Nature. 403:503–511. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lenz G, Wright G, Dave SS, Xiao W, Powell
J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, et al: Stromal gene
signatures in large-B-cell lymphomas. N Engl J Med. 359:2313–2323.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Coiffier B, Lepage E, Briere J, Herbrecht
R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G,
Gaulard P, et al: CHOP chemotherapy plus rituximab compared with
CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
N Engl J Med. 346:235–242. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nowakowski GS and Czuczman MS: ABC, GCB
and double-hit diffuse large B-cell lymphoma: Does subtype make a
difference in therapy selection? Am Soc Clin Oncol Educ Book.
e449–e457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kawai T and Akira S: The role of
pattern-recognition receptors in innate immunity: Update on
Toll-like receptors. Nat Immunol. 11:373–384. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lim KH, Yang Y and Staudt LM: Pathogenetic
importance and therapeutic implications of NF-κB in lymphoid
malignancies. Immunol Rev. 246:359–378. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Davis RE, Brown KD, Siebenlist U and
Staudt LM: Constitutive nuclear factor kappaB activity is required
for survival of activated B cell-like diffuse large B cell lymphoma
cells. J Exp Med. 194:1861–1874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ngo VN, Young RM, Schmitz R, Jhavar S,
Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, et al:
Oncogenically active MYD88 mutations in human lymphoma. Nature.
470:115–119. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim Y, Ju H, Kim DH, Yoo HY, Kim SJ, Kim
WS and Ko YH: CD79B and MYD88 mutations in diffuse large B-cell
lymphoma. Hum Pathol. 45:556–564. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Choi JW, Kim Y, Lee JH and Kim YS: MYD88
expression and L265P mutation in diffuse large B-cell lymphoma. Hum
Pathol. 44:1375–1381. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Taniguchi K, Takata K, Chuang SS,
Miyata-Takata T, Sato Y, Satou A, Hashimoto Y, Tamura M, Nagakita
K, Ohnishi N, et al: Frequent MYD88 L265P and CD79B mutations in
primary breast diffuse large B-cell lymphoma. Am J Surg Pathol.
40:324–334. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fernándezrodríguez C, Bellosillo B,
Garcíagarcía M, Sánchez-González B, Gimeno E, Vela MC, Serrano S,
Besses C and Salar A: MYD88 (L265P) mutation is an independent
prognostic factor for outcome in patients with diffuse large B-cell
lymphoma. Leukemia. 28:2104–2106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pham-Ledard A, Beylot-Barry M, Barbe C,
Leduc M, Petrella T, Vergier B, Martinez F, Cappellen D, Merlio JP
and Grange F: High frequency and clinical prognostic value of MYD88
L265P mutation in primary cutaneous diffuse large B-cell lymphoma,
leg-type. JAMA Dermatol. 150:1173–1179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rovira J, Karube K, Valera A, Colomer D,
Enjuanes A, Colomo L, Martínez-Trillos A, Giné E, Dlouhy I, Magnano
L, et al: MYD88 L265P mutations, but no other variants, identify a
subpopulation of DLBCL patients of activated B-cell origin,
extranodal involvement and poor outcome. Clin Cancer Res.
22:2755–2764. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hattori K, Sakata-Yanagimoto M, Okoshi Y,
Goshima Y, Yanagimoto S, Nakamoto-Matsubara R, Sato T, Noguchi M,
Takano S, Ishikawa E, et al: MYD88 (L265P) mutation is associated
with an unfavourable outcome of primary central nervous system
lymphoma. Br J Haematol. 177:492–494. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Steinhardt JJ and Gartenhaus RB: Promising
personalized therapeutic options for diffuse large B-cell lymphoma
subtypes with oncogene addictions. Clin Cancer Res. 18:4538–4548.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dunleavy K, Pittaluga S, Czuczman MS, Dave
SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM and
Wilson WH: Differential efficacy of bortezomib plus chemotherapy
within molecular subtypes of diffuse large B-cell lymphoma. Blood.
113:6069–6076. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Swerdllow SH, Campo E, Harris NL, Jaffe
ES, Pileri SA, Stein H, Thiele J and Vardiman JW: WHO
classification of tumours of haematopoietic and lymphoid tissues.
2. 4th. IARC Press; France: pp. 4392008
|
|
20
|
Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E,
Braziel RM, Jaffe ES, et al: Confirmation of the molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 103:275–282.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y,
Liu X, Morra E, Trojani A, Greco A, Arcaini L, et al: MYD88 L265P
in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal
gammopathy, and other B-cell lymphoproliferative disorders using
conventional and quantitative allele-specific polymerase chain
reaction. Blood. 121:2051–2058. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kraan W, Horlings HM, van Keimpema M,
Schilder-Tol EJ, Oud ME, Scheepstra C, Kluin PM, Kersten MJ,
Spaargaren M and Pals ST: High prevalence of oncogenic MYD88 and
CD79B mutations in diffuse large B-cell lymphomas presenting at
immune-privileged sites. Blood Cancer J. 3:e1392013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rossi D: Role of MYD88 in
lymphoplasmacytic lymphoma diagnosis and pathogenesis. Hematology
Am Soc Hematol Educ Program. 2014:113–118. 2014.PubMed/NCBI
|
|
24
|
Staiger AM, Ott MM, Parmentier S,
Rosenwald A, Ott G, Horn H and Griese EU: Allele-specific PCR is a
powerful tool for the detection of the MYD88 L265P mutation in
diffuse large B cell lymphoma and decalcified bone marrow samples.
Br J Haematol. 171:145–148. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fernández-Rodriguez C, Bellosillo B,
Garcia-Garcia M, Sánchez-González B, Gimeno E, Vela MC, Serrano S,
Besses C and Salar A: MYD88 (L265P) mutation is an independent
prognostic factor for outcome in patients with diffuse large B-cell
lymphoma. Leukemia. 28:2104–2106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Eliopoulos AG, Stack M, Dawson CW, Kaye
KM, Hodgkin L, Sihota S, Rowe M and Young LS: Epstein-Barr
virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial
cells via an NF-kappaB pathway involving TNF receptor-associated
factors. Oncogene. 14:2899–2916. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Caner V, Sen Turk N, Baris IC, Cetin GO,
Tepeli E, Hacioglu S, Sari I, Zencir S, Dogu MH, Bagci G and Keskin
A: MYD88 expression and L265P mutation in mature B-cell non-Hodgkin
lymphomas. Genet Test Mol Biomarkers. 19:372–378. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Landau DA, Carter SL, Stojanov P, et al:
Evolution and impact of subclonal mutations in chronic lymphocytic
leukemia. Cell. 152:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Klapper W, Kreuz M, Kohler CW, Burkhardt
B, Szczepanowski M, Salaverria I, Hummel M, Loeffler M, Pellissery
S, Woessmann W, et al: Patient age at diagnosis is associated with
the molecular characteristics of diffuse large B-cell lymphoma.
Blood. 119:1882–1887. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee JH, Jeong H, Choi JW, Oh H and Kim YS:
Clinicopathologic significance of MYD88L265P mutation in diffuse
large B-cell lymphoma: A meta-analysis. Sci Rep. 7:17852017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim Y, Ju H, Kim DH, Yoo HY, Kim SJ, Kim
WS and Ko YH: CD79B and MYD88 mutations in diffuse large B-cell
lymphoma. Hum Pathol. 45:556–564. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kraan W, Horlings HM, van Keimpema M,
Schilder-Tol EJ, Oud ME, Scheepstra C, Kluin PM, Kersten MJ,
Spaargaren M and Pals ST: High prevalence of oncogenic MYD88 and
CD79B mutations in diffuse large B-cell lymphomas presenting at
immune-privileged sites. Blood Cancer J. 3:e1392013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rovira J, Karube K, Valera A, Colomer D,
Enjuanes A, Colomo L, Martínez-Trillos A, Giné E, Dlouhy I, Magnano
L, et al: MYD88 L265P mutations, but no other variants, identify a
subpopulation of DLBCL patients of activated B-cell origin,
extranodal involvement and poor outcome. Clin Cancer Res.
22:2755–2764. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y,
Liu X, Morra E, Trojani A, Greco A, Arcaini L, et al: MYD88 L265P
in Waldenström macroglobulinemia, immunoglobulin M monoclonal
gammopathy, and other B-cell lymphoproliferative disorders using
conventional and quantitative allele-specific polymerase chain
reaction. Blood. 121:2051–2058. 2013. View Article : Google Scholar : PubMed/NCBI
|
